title: A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
abstract: OBJECTIVE
  To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease.
  
  
  METHODS
  Patients with corticosteroid-dependent Crohn's disease (use of prednisolone 15-40 mg/day or budesonide 9 mg/day for at least 8 weeks, a previous failed attempt to discontinue corticosteroids within 8 weeks, and Crohn's Disease Activity Index score 150 points or less) were enrolled in a 16-week, randomized, double-blind, placebo-controlled trial. The patients received intravenous CDP571 (20 mg/kg at week 0 and 10 mg/kg at week 8) or placebo. Corticosteroid therapy was decreased following a predefined schedule. The primary efficacy end-point was the percentage of patients with corticosteroid-sparing [i.e. no disease flare (Crohn's Disease Activity Index score > or =220 points) and no longer requiring corticosteroid therapy] at week 10. The major secondary efficacy end-point was corticosteroid-sparing at week 16.
  
  
  RESULTS
  Seventy-one patients received treatment. Corticosteroid-sparing was achieved by 19 of 39 (48.7%) CDP571 patients and 13 of 42 (40.6%) placebo patients (P = 0.452) at week 10, and by 18 of 39 (46.2%) CDP571 patients and seven of 32 (21.9%) placebo patients (P = 0.032) at week 16. CDP571 therapy was well-tolerated and the incidence of serious adverse events was similar to placebo.
  
  
  CONCLUSIONS
  The CDP571 was effective for corticosteroid-sparing at week 16 but not week 10, and was well-tolerated in patients with corticosteroid-dependent Crohn's disease.
authors.affiliation: The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada. bfeagan@robarts.ca
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
authors.forename: W J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: J P
authors.initials: JP
authors.lastname: Baker
authors.forename: F
authors.initials: F
authors.lastname: Cominelli
authors.forename: L R
authors.initials: LR
authors.lastname: Sutherland
authors.forename: C O
authors.initials: CO
authors.lastname: Elson
authors.forename: B A
authors.initials: BA
authors.lastname: Salzberg
authors.forename: A
authors.initials: A
authors.lastname: Archambault
authors.forename: C N
authors.initials: CN
authors.lastname: Bernstein
authors.forename: G R
authors.initials: GR
authors.lastname: Lichtenstein
authors.forename: P K
authors.initials: PK
authors.lastname: Heath
authors.forename: S
authors.initials: S
authors.lastname: Cameron
authors.forename: S B
authors.initials: SB
authors.lastname: Hanauer
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; C402162:CDP 571; D019819:Budesonide; D011239:Prednisolone